Latest Headlines

61. Broad-Spectrum Antiviral Candidate Targets Dengue And SARS-CoV-2 10/20/2023

    A broad-spectrum antiviral drug candidate, 2-thiouridine, that targets positive-strand RNA viruses has been identified and characterized.

62. Towards Using Quantum Computing To Speed Up Drug Development 10/20/2023

    Researchers have developed a quantum processor that can perform crucial drug design methods, which could lead to more efficient drug development.

63. Newly Discovered Compound Blocks Signalling Pathway Of Immune Response 10/20/2023

    Scientists at CeMM, the Medical University of Vienna and the University of Lausanne succeeded for the first time in identifying and characterizing a new small molecule called "Feeblin", which can inhibit the interaction of the transporter protein SLC15A4 with the adapter protein TASL.

64. St Andrews Scientists Discover New Molecule That Combats Viral Infection In Bacteria 10/19/2023

    A PhD researcher at the University of St Andrews studying microbes in the human gut has discovered a new molecule that acts as a ‘distress signal’ when viruses are detected.

65. New ‘Subway Map’ Of Lyme Disease Pathways Identifies Potential New Treatment Targets 10/19/2023

    Scientists at Tufts University School of Medicine and the Graduate School of Biomedical Sciences (GSBS) have developed a genome-scale metabolic model or “subway map” of key metabolic activities of the bacterium that causes Lyme disease. Using this map, they have successfully identified two compounds that selectively target routes only used by Lyme disease to infect a host. Their research was published October 19 in the journal mSystems.

66. Yeast Speeds Discovery Of Medicinal Compounds In Plants 10/18/2023

    Cornell researchers have harnessed the power of baker’s yeast to create a cost-effective and highly efficient approach for unraveling how plants synthesize medicinal compounds, and used the new method to identify key enzymes in a kratom tree.

67. Wyss Institute At Harvard University Wins BARDA Contract To Leverage Human Organ Chips To Advance Knowledge And Drug Discovery For Broad Range Of Health Security Threats 10/18/2023

    The Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), partnered with the Wyss Institute at Harvard University to support the Institute in advancing its human Organ Chip platform and drug discovery capabilities to better understand the illness and injuries that result from a broad range of health security threats, including high doses of radiation, as well as predicting and evaluating potential treatments.

68. Fighting Antimicrobial Resistance With New Drug Combinations 10/17/2023

    Antimicrobial resistance – occurring when pathogens can survive antibiotic treatment – is one of the most rapidly emerging global public health threats today.

69. Nkarta Receives FDA Clearance Of IND Application For NKX019 In Lupus Nephritis 10/17/2023

    Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced the clearance of an Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to evaluate NKX019, its allogeneic, CD19-directed CAR NK cell therapy candidate, for the treatment of lupus nephritis.

70. Servier Partners With Owkin With The Aim Of Discovering And Developing AI-Driven Precision Therapeutics 10/17/2023

    Servier, a global independent pharmaceutical group, and Owkin, a French American biotech focused on applying artificial intelligence (AI) to drug discovery, development, and diagnostics, today announced an innovative partnership to use AI to advance and accelerate better-targeted therapies across multiple disease areas, including oncology.